Novo heads to regulators after Sogroya matches predecessor Norditropin in 3 pediatric growth disorders
Novo Nordisk has unveiled data from the phase 3 REAL8 trial, which found that the company’s once-weekly human growth hormone analogue Sogroya was largely on par with its daily predecessor, Norditropin, in a trio of growth disorders in kids.
Novo Nordisk has unveiled data from the phase 3 REAL8 trial, which found that the company’s once-weekly human growth hormone analogue Sogroya was largely on par with its daily predecessor, Norditropin, in a trio of growth disorders in kids.
